Fig. 3From: Perspectives in Immunotherapy: meeting report from the Immunotherapy Bridge, December 1st–2nd, 2021First line trials with combination strategies including PARPi + IO in ovarian cancer. Levinson et al. ASCO Ed. Book (2019)Back to article page